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Glucose feeds the TCA cycle via circulating lactate
Sheng Hui1,2, Jonathan m. Ghergurovich1,3, raphael J. morscher1,2, Cholsoon Jang1,2, Xin Teng1,2, Wenyun Lu1,2, 
Lourdes A. esparza4, Tannishtha reya4,   Le Zhan5,6, Jessie Yanxiang Guo5,7,8, eileen White5,6 & Joshua D. rabinowitz1,2,5
Mammalian tissues are fuelled by circulating nutrients, including 
glucose, amino acids, and various intermediary metabolites. Under 
aerobic conditions, glucose is generally assumed to be burned fully 
by tissues via the tricarboxylic acid cycle (TCA cycle) to carbon 
dioxide. Alternatively, glucose can be catabolized anaerobically 
via glycolysis to lactate, which is itself also a potential nutrient for 
tissues1 and tumours2–5. The quantitative relevance of circulating 
lactate or other metabolic intermediates as fuels remains unclear. 
Here we systematically examine the fluxes of circulating metabolites 
in mice, and find that lactate can be a primary source of carbon 
for the TCA cycle and thus of energy. Intravenous infusions of 
13C-labelled nutrients reveal that, on a molar basis, the circulatory 
turnover flux of lactate is the highest of all metabolites and exceeds 
that of glucose by 1.1-fold in fed mice and 2.5-fold in fasting mice; 
lactate is made primarily from glucose but also from other sources. 
In both fed and fasted mice, 13C-lactate extensively labels TCA cycle 
intermediates in all tissues. Quantitative analysis reveals that during 
the fasted state, the contribution of glucose to tissue TCA metabolism 
is primarily indirect (via circulating lactate) in all tissues except the 
brain. In genetically engineered lung and pancreatic cancer tumours 
in fasted mice, the contribution of circulating lactate to TCA cycle 
intermediates exceeds that of glucose, with glutamine making a 
larger contribution than lactate in pancreatic cancer. Thus, glycolysis 
and the TCA cycle are uncoupled at the level of lactate, which is a 
primary circulating TCA substrate in most tissues and tumours.
Mammals generate energy by catabolizing food into carbon dioxide 
(CO2). Glucose is generally assumed to be catabolized in cells via the 
concerted action of glyco lysis and the TCA cycle. Cells and tissues can 
also share metabolic tasks by exchanging intermediary metabolites, 
such as lactate. Here we systematically investigate the significance of 
different circulating metabolic intermediates. The circulatory turn­
over flux (Fcirc) of a given metabolite refers to the rate at which tissues 
collectively consume the metabolite from the arterial circulation (Fc) 
and produce and excrete the metabolite into the venous circulation (Fp) 
(Fig. 1a), with these two rates being equal at steady state. We considered 
whether there is any fundamental limit on which metabolites can have 
high Fcirc (that is, can contribute substantially to inter­organ fluxes). 
For metabolite M, its consumption by the tissues cannot occur faster 
than the rate at which it is pumped from the heart:
≤ ×F Mcardiac output [ ] (1)circ
Thus, only metabolites that are reasonably concentrated in blood can 
contribute substantially to inter­organ fluxes, with 39 metabolites in mice 
having a sufficient concentration (greater than 30 μ M) to potentially have 
greater than 10% of the Fcirc of glucose6 (Extended Data Fig. 1).
We measured Fcirc for most of these species following an approach 
classically used to measure whole­body glucose production flux7: for 
each metabolite M, a trace amount of 13C­labelled M is infused into the 
circulation at a constant rate R until steady­state labelling is achieved 
(Fig. 1b,c), at which point the labelled fraction L is related to the turn­
over flux as:
=
−
F
R L
L
(1 )
(2)circ
For derivation, see Supplementary Note 1. Infusions were into the right 
jugular vein of freely moving C57BL/6 mice that had been fasted for 
8 h (Extended Data Fig. 2a), with measurements of serum labelling 
via liquid chromatography–mass spectrometry (LC–MS). Despite glu­
cose being widely assumed to be the predominant circulating carbon 
source, on a molar basis, lactate showed a 2.5­fold higher circulatory 
turnover flux (1.25­fold higher on a per­carbon­atom basis) (Fig. 1d 
and Extended Data Fig. 2b–d). The other metabolites with substantial 
circulatory turnover fluxes (greater than 20% of glucose on a molar 
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Figure 1 | Turnover fluxes of circulating metabolites in fasting mice. 
a, Illustration of circulatory turnover flux (Fcirc) and its determination by 
isotope tracing. b, c, Kinetics of isotopic labelling of circulating glucose 
and lactate. Data from different mice are indicated by different symbols 
and are fitted with a single exponential. d, Glucose (n = 22) and lactate 
(n = 24) turnover fluxes; data are mean ±  s.d. e, Turnover fluxes of amino 
acids versus their average abundances in mammalian proteins. Blue 
asterisks, essential amino acids (EAAs). Data are mean ± s.d.; n = 5 for 
glutamine; n = 4 for essential amino acids except tyrosine; n = 3 for other 
amino acids). In all figures, n = number of mice.
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basis) were pyruvate, glycerol, acetate, 3­hydroxybutyrate, alanine and 
glutamine, each of which had a turnover flux less than 20% that of 
lactate (Table 1). Fcirc of free palmitate was 15% that of glucose on a 
molar basis, which equals 40% on a carbon atom basis. Essential amino 
acids, which are not biosynthesized and come from either diet or tissue 
protein degradation, exhibited lower Fcirc values, which were propor­
tional to the abundances of the amino acids in protein (Fig. 1e). Like 
lactate, infused pyruvate was rapidly consumed by tissues, but its 
circulating concentration is too low to carry comparable flux (equation 
(1) and Supplementary Note 1).
Previous Fcirc measurements have been largely restricted to 
glucose. However measurements have been reported for lactate and, 
consistent with our data, showed lactate turnover flux in excess of 
glucose turnover flux8–11. The physiological significance of these 
measurements has generally been dismissed, on the basis of the 
assumption that high lactate turnover flux merely reflects rapid 
lactate–pyruvate exchange. In actuality, such exchange does not change 
the 13C­labelling pattern of lactate and therefore does not contribute to 
turnover flux. Rather, the measured lactate circulatory turnover flux 
reflects the whole­body pyruvate production rate, multiplied by the 
fraction of tissue pyruvate that is excreted into the circulation as lactate 
(Supplementary Note 2 and Extended Data Fig. 3a). Thus, high 
lactate Fcirc reflects a high fraction of tissue pyruvate being excreted 
as lactate (and a high fraction of tissue pyruvate being derived from 
circulating lactate).
Another concern with regards to prior measurements is differences 
in arterial and venous lactate labelling12–16. We modelled the origin of 
such differences using partial differential equations to examine label­
ling across a tissue capillary bed (Supplementary Note 1 and Extended 
Data Fig. 3b). We find that the difference in arterial and venous 
labelling (La −  Lv = Δ L) depends on the relative magnitude of Fcirc 
compared to metabolite flow:
Δ =
×
L
L
F
Mcardiac output [ ] (3)a
circ
In cases of substantial Δ L, Fcirc can be determined by equation (3) or 
by equation (2) with L the arterial metabolite labelling, with similar 
results (Supplementary Note 1). Thus, rather than precluding accurate 
determination of Fcirc, the arterial–venous difference in lactate labelling 
(Extended Data Fig. 3c) confirms the high circulatory turnover flux 
of lactate.
To test the hypothesis that lactate is a primary circulating carbon 
carrier, we examined tissue metabolite labelling after infusing uniformly 
13C­labelled forms of the two primary carbon sources in cell culture 
 (glucose and glutamine) or lactate. At steady state (Extended Data Fig. 4), 
the normalized labelling of a tissue metabolite from a circulating 
nutrient (Lmetabolite←nutrient) is defined as the fraction of 13C atoms in the 
metabolite, normalized to the fraction of 13C atoms in the  circulating 
nutrient17–19. As expected, normalized labelling of glycolytic and 
 pentose phosphate intermediates in tissue was greatest from the  glucose 
infusion, whereas tissue lactate was labelled substantially from both 
glucose and lactate tracer infusions (Extended Data Fig. 5). In most 
tissues, normalized labelling of TCA intermediates, as represented by 
malate and succinate (Extended Data Fig. 6), was greatest from the 
lactate infusion (Fig. 2a–c).
Although normalized TCA labelling from lactate (LTCA←lac) generally 
exceeded that from glucose (LTCA←glc), the difference was, on average, 
modest (approximately 30% versus approximately 20%). A substantial 
fraction of serum lactate was, however, derived from glucose (red bar in 
Fig. 2b). We denote the fraction of 13C atoms in serum lactate following 
labelled glucose infusion, normalized to the fraction of 13C atoms in 
serum glucose, as Llac←glc. Measurement of LTCA←lac and Llac←glc allows 
us to determine quantitatively how much of the TCA labelling from 
labelled glucose infusion actually arises through labelled circulating 
lactate (LTCA←lac·Llac←glc). This amount is shown as the solid line in 
Fig. 2d. Within the margins of error, TCA labelling from glucose is 
fully accounted for by labelling through circulating lactate in every 
tissue exept for the brain.
Analogously, labelled lactate infusion contributes to TCA labelling 
through labelled circulating glucose produced by gluconeogenesis 
Table 1 | Turnover fluxes for different circulating carbon metabolites
Metabolite
Fcirc  
(nmol g−1 min−1) Metabolite
Fcirc  
(nmol g−1 min−1)
Lactate 374.4 ± 112.4 Arginine 9.0 ± 2.6
Glucose 150.9 ± 46.7 Tyrosine 8.0 ± 2.2
Acetate 72.7 ± 17.5 Threonine 7.6 ± 0.8
Alanine 70.2 ± 5.4 Proline 7.3 ± 2.9
Pyruvate 57.3 ± 14.2 Isoleucine 6.5 ± 0.7
Glycerol 53.3 ± 2.1 Asparagine 6.5 ± 0.8
Glutamine 45.6 ± 4.7 Phenylalanine 5.9 ± 0.8
3-Hydroxybutyrate 43.3 ± 17.1 2-Oxoglutarate 5.8 ± 0.8
Palmitic acid 24.6 ± 4.2 Histidine 5.0 ± 0.4
Glycine 21.9 ± 4.2 Methionine 3.9 ± 1.6
Taurine 19.4 ± 0.9 Succinate 3.1 ± 1.1
Serine 19.3 ± 4.2 Creatine 2.6 ± 0.5
Citrate 16.2 ± 6.6 Tryptophan 2.3 ± 0.3
Leucine 11.5 ± 1.2 Malate 2.0 ± 0.4
Valine 9.6 ± 0.4 Betaine 1.6 ± 0.2
Lysine 9.3 ± 1.8
n = 24 for lactate; n = 22 for glucose; n = 5 for glutamine; n = 4 for 3-hydroxybutyrate; n = 5 for 
palmitic acid; n = 4 for essential amino acids; n = 3 for others; mean ± s.d.
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Figure 2 | In fasting mice, glucose labels TCA intermediates through 
circulating lactate in all tissues except the brain. a–c, Normalized 
labelling of serum glucose, lactate, and glutamine, and of tissue TCA 
intermediates by infused 13C­lactate (a, n = 4), 13C­glucose (b, n = 5), 
and 13C­glutamine (c, n = 3). Data are mean ± s.d. d, Scatter plot of 
normalized labelling of TCA intermediates by infused 13C­glucose versus 
infused 13C­lactate (13C­glucose and 13C­lactate experiments performed 
separately). The solid line represents the expected labelling by 13C­glucose 
assuming that glucose feeds the TCA cycle solely through circulating 
lactate. The dashed line indicates the expected labelling by 13C­lactate 
assuming that lactate feeds the TCA cycle solely through circulating 
glucose. Data are from a and b, each data point is one TCA intermediate 
in one tissue, mean ± s.d., n = 4 for 13C­lactate infusion and n = 5 for 
13C­glucose infusion. e, Direct circulating nutrient contributions to tissue 
TCA cycle (see Supplementary Note 3), data are mean ± s.e.m. f, Steady­
state whole­body flux model of interconversion between circulating 
glucose and lactate and their feeding of TCA (see Supplementary Note 4), 
data are mean ± s.e.m.
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(LTCA←glc · Lglc←lac, dashed line in Fig. 2d). To quantitatively delineate 
the direct flux contributions to the TCA cycle by circulating glucose, 
lactate, and glutamine, we developed a linear algebra model to com­
pute the direct TCA substrate usage of individual tissues (Fig. 2e and 
Supplementary Note 3). This analysis confirmed that, except in the 
brain, direct glucose flux to the TCA cycle is close to zero in fasted mice. 
Glutamine and lactate together account for about half of TCA cycle 
carbon. It is likely that most of the remainder comes from a combi­
nation of other amino acids and fat. Thus, in the fasted state, glucose 
feeds the TCA cycle mainly via circulating lactate in all tissues but 
the brain.
At the whole­body level, the circulatory turnover fluxes of glu­
cose and lactate and their overall interconversion in body tissue can 
be quantitatively accounted for by a steady­state flux balance model 
(Supplementary Note 4), with fluxes determined solely on the basis of 
labelling of circulating glucose and lactate. In fasting mice, modelling 
revealed that the majority of glucose enters the TCA via circulating 
lactate (Fig. 2f). Similar relative contributions of glucose and lactate 
were also observed in anaesthetized mice (Extended Data Fig. 7).
We next examined fluxes of glucose and lactate in fed mice, where 
insulin signalling could increase tissue glucose metabolism. Indeed, 
Fcirc for glucose was 3.1­fold higher than in fasted mice. This was 
accompanied by a small increase in Fcirc for lactate, which was about 
1.1­fold of Fcirc for glucose on a molar basis (55% on a per­carbon­atom 
basis) (Fig. 3a). TCA labelling from glucose also increased (Extended 
Data Fig. 8), with glucose and lactate making a roughly equal direct 
contribution to the muscle TCA cycle. In other organs, even in the fed 
state, glucose contributes to the TCA cycle mostly through circulating 
lactate (Fig. 3b, c). Quantitative whole­body modelling showed that, 
in the fed state, about 40% of glucose feeds the TCA cycle through 
circulating lactate (Fig. 3d and Supplementary Note 4). Further work 
is required to assess other states, such as exercise, and to identify the 
tissue compartments responsible for glucose­to­lactate flux.
Rapid glucose catabolism to lactate was the first molecular phenotype 
assigned to cancer20,21. Tumours are often thought of as having an iso­
lated metabolic microenvironment owing to poor perfusion, in which 
local exchange of nutrients (for example, between cancer cells and stro­
mal cells) predominates over nutrient exchange with the circulation. We 
measured TCA substrate contributions in three genetically engineered 
mouse models (GEMMs). Notably, in all three cases, the contribu­
tion of circulating lactate to tumour TCA intermediates exceeded 
that of glucose by about twofold (Fig. 4a–c), with quantitative analysis 
consistent with glucose contributing to the tumour TCA cycle only 
through circulating lactate (Extended Data Fig. 9). Thus, the GEMM 
tumours that we studied are thoroughly perfused by lactate. This does 
not rule out the potential for some sections within human tumours 
to be less well perfused5 or for an important subset of tumour cells 
to be isolated within a poorly perfused metabolic niche. Note that in 
normal lung tissue and lung cancer, the largest TCA contribution was 
from lactate, whereas in the pancreas and pancreatic cancer, glutamine 
contributed more (Figs 2e and 4d), consistent with tumours mirroring 
the substrate preferences of their tissues of origin22,23.
It is useful to differentiate between the above conclusions that arise 
directly from experimental data and those that are inferred on the basis 
of quantitative modelling, which omits certain biological complexity, 
such as tissue heterogeneity. The experimental data demonstrate that 
circulating lactate is a major source of TCA intermediates. The quanti­
tative modelling leads to the additional conclusion that, in most tissues 
and GEMM tumours, the contribution of glucose to the TCA cycle is 
mostly through circulating lactate.
The metabolic role of lactate is well recognized, including as a fuel for 
tissues24 and tumours2–5,25. In the classical Cori cycle, muscle produces 
lactate which is then taken up by the liver for gluconeogenesis. Previous 
work has highlighted the potential for lactate to shuttle carbon both 
between and within tissues26–29. We find that such shuttling under­
lies the majority of circulating lactate turnover, with glucose feeding 
TCA metabolism mainly through circulating lactate (Fig. 4e). This 
picture requires high lactate dehydrogenase (LDH) activity and rapid 
lactate transport across the plasma membrane. Mammals encode two 
ubiquitously expressed LDH isozymes (LDHA and LDHB), as well as 
four monocarboxylate transporters (MCT1–MCT4). While the dif­
ferent isozymes show some kinetic differences, the direction of net 
flux is determined by thermodynamics. Genetic manipulation of these 
0
600
800
Fl
ux
 (n
m
ol
 g
–1
 m
in
–1
)
Glucose Lactate Glutamine
**
400
200 **
****
 0
0.2
0.4
0.6
0.8
1.0
Fr
ac
tio
n
a
b d
c
0
0.2
0.4
0.6
0.8
1.0
Brain
Heart
Muscle
 
 
Circulating
glucose
Tissue
TCA
Circulating
lactate 
1,070 ± 160
340 ± 40
400 ± 80
1,140 ± 120
2,500 ± 260
1,750 ± 320
Whole-body flux
Units: nmol of C per g per min
N
or
m
al
iz
ed
 la
b
el
lin
g
b
y 
13
C
-g
lu
co
se
0 0.2 0.4 0.6 0.8 1.0
Normalized labelling by 13C-lactate
Malate
Succinate
Glucose
Glutamine
Fed
Fasted Lactate
Br
ain
Ki
dn
ey
M
us
cle
Liv
er
Sp
lee
n
Pa
nc
re
as
Lu
ng
He
ar
t
Ad
ipo
se
 tis
su
e
Sm
all
 in
te
sti
ne
Figure 3 | In fed mice, in all tissues except brain and muscle, glucose 
labels TCA intermediates mostly through circulating lactate. 
a, Turnover fluxes of glucose, lactate, and glutamine in fed and fasted mice 
(fed state: n = 5 for glucose, n = 12 for lactate, and n = 6 for glutamine; 
fasting state: n = 22 for glucose, n = 24 for lactate, and n = 5 for glutamine). 
Data are mean ± s.d., * * * * P < 0.0001; * * P < 0.002 by t­test. b, Normalized 
labelling of TCA intermediates by 13C­glucose versus 13C­lactate, as in  
Fig. 2d, in fed mice. Data are from Extended Data Fig. 8. c, Direct 
circulating nutrient contributions to the tissue TCA cycle in fed mice; data 
are mean ± s.e.m. d, Steady­state whole­body flux model, as in Fig. 2f, in 
fed mice; data are mean ± s.e.m.
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enzymes and transporters will be important to establish the biochem­
ical basis of the phenomena reported here.
Among the many metabolic intermediates, why does lactate carry 
high flux? Lactate is redox­balanced with glucose. The rapid exchange 
of both tissue lactate and pyruvate with the circulation may help to 
equate cytosolic NAD+/NADH ratios across tissues, allowing the whole 
body to buffer NAD(H) disturbances in any given location30. Nearly 
complete lactate sharing between tissues effectively decouples glyco­
lysis and the TCA cycle in individual tissues, allowing independent 
tissue­specific regulation of both processes. Because almost all ATP is 
made in the TCA cycle, each tissue can acquire energy from the largest 
dietary calorie constituent (carbohydrate) without needing to carry out 
glycolysis. In turn, glycolytic activity can be modulated to support cell 
proliferation, NADPH production by the pentose phosphate pathway, 
brain activity, and systemic glucose homeostasis21. In essence, by having 
glucose feed the TCA cycle via circulating lactate, the housekeeping 
function of ATP production is decoupled from glucose catabolism. In 
turn, glucose metabolism is regulated to serve more advanced objec­
tives of the organism.
Online Content Methods, along with any additional Extended Data display items and 
Source Data, are available in the online version of the paper; references unique to 
these sections appear only in the online paper.
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MeThODS
Data reporting. No statistical methods were used to predetermine sample size. 
The experiments were not randomized.
Intravenous infusion of wild-type C57BL/6 mice. Animal studies followed pro­
tocols approved by the Princeton University Institutional Animal Care and Use 
Committee. In vivo infusions were performed on 12–14­week­old C57BL/6 mice 
pre­catheterized in the right jugular vein (Charles River Laboratories). Mice were 
randomly chosen for infusions of different tracers. No blinding was performed. 
A minimum of three mice was used for each tracer. To collect arterial blood sam­
ples, we used mice pre­catheterized in both the right jugular vein and left carotid 
artery (Charles River Laboratories), infusing through the venous catheter and 
drawing blood from the arterial catheter. Venous samples were taken from tail 
bleeds. The mice were on a normal light cycle (8:00–20:00). On the day of the 
infusion experiment, mice were transferred to new cages without food around 8:00 
(beginning of their sleep cycle) and infused for 2.5 h starting at around 14:00. To 
analyse the fed state, the mice were maintained without food until around 19:00, at 
which time chow was placed back in the cages and the 2.5 h infusion initiated. The 
mouse infusion setup (Instech Laboratories) included a tether and swivel system 
so that the animal had free movement in the cage. Water­soluble isotope­labelled 
metabolites (Cambridge Isotope Laboratories) were prepared as solutions in 
sterile normal saline and infused via the catheter at a constant rate for 2.5 h (unless 
otherwise indicated). To make 13C­palmitate solution, [U­13C]sodium palmitate 
was complexed with bovine serum albumin in a 2:1 molar ratio 31. Detailed infu­
sion parameters are listed in Supplementary Table 1. Blood samples (~ 20 μ l) were 
placed on ice in the absence of anticoagulant, and centrifuged at 4 °C to isolate 
serum. At the end of the infusion, the mouse was euthanized by cervical dislo­
cation and tissues were quickly dissected and snap frozen in liquid nitrogen with 
pre­cooled Wollenberger clamp32. Serum and tissue samples were kept at − 80 °C 
until LC–MS or GC–MS analysis.
Intravenous infusion of genetically engineered mouse models. Animal studies 
with the lung cancer GEMMs followed protocols approved by the Rutgers University 
Institutional Animal Care and Use Committee. KrasLSL-G12D/+Trp53flox/flox  
(KP) and KrasLSL-G12D/+Stk11flox/flox (Stk11 is also known as Lkb1 and the mouse 
model is referred to as the KL lung cancer model) mice were intranasally infected 
with recombinant, replication­deficient adenovirus expressing Cre recombi­
nase (University of Iowa Adenoviral Core) at 4 × 107 plaque­forming units per 
mouse at 6–8 weeks of age. At 12 weeks post­infection, catheters were surgically 
implanted into the right jugular vein of KP and KL GEMMs and [U­13C]glucose 
(0.2 M, 0.1 μ l g−1 min−1), [U­13C]glutamine (0.1 M, 0.1 μ l g−1 min−1), or [U­13C]
sodium lactate (5% w/w, 0.1 μ l g−1 min−1) was infused into 8­h fasted mice for 
2.5 h. Blood samples were collected from the tail vein and facial vein for measure­
ment of serum enrichment of isotopic tracers. Mice were euthanized by cervical 
dislocation and tumours were quickly snap frozen in liquid nitrogen using a pre­
cooled Wollenberger clamp. Throughout the experiments, mice were examined 
for evidence of distress due to lung tumour progression (for example, difficulty 
breathing, difficulty moving, significant weight loss, or moribund status) every day 
to ensure the health and well­being of the animal. Any animals exhibiting signs of 
distress would have been euthanized. At the time of in vivo infusion, none of the 
mice showed signs of distress.
Animal studies with the pancreatic cancer GEMM followed protocols approved 
by the University of California at San Diego Institutional Animal Care and Use 
Committee. KrasLSL-G12D/+Trp53flox/floxPtf1aCRE/+ (KPf/fC) mice were used. While 
Kras mutation alone leads to PanIN formation33, when combined with deletion of 
Trp53 it drives progression to adenocarcinoma34. At ~ 10 weeks old, catheters were 
surgically implanted into the right jugular vein of KPf/fC mice and [U­13C]glucose 
(0.2 M, 0.1 μ l g−1 min−1), [U­13C]glutamine (0.1 M, 0.1 μ l g−1 min−1), or [U­13C]
sodium lactate (5% w/w, 0.1 μ l g−1 min−1) was infused into 8­h fasted mice for 2.5 h. 
Blood samples were collected from the tail vein for measurement of serum enrich­
ment of isotopic tracers. Mice were euthanized by cervical dislocation, and tumours 
were quickly snap frozen in liquid nitrogen using a pre­cooled Wollenberger clamp. 
Throughout the experiments, tumour progression was monitored according to 
protocols approved by the University of California San Diego Institutional Animal 
Care and Use Committee: weekly (for no visible, palpable, clinical, or behavioural 
signs of tumour burden), twice weekly (for visible or palpable tumours; changes in 
appearance or behaviour), and/or daily (for any signs of morbidity or mortality). It 
is important to note that with our pancreatic cancer model, in most instances, the 
mice show no visible signs of disease—no palpable tumour, no lethargy, no hunch­
ing, no weight loss, although we monitored carefully for these signs of distress.
Metabolite measurement. Metabolites were extracted from serum samples 
(thawed on ice) by adding 65 μ l 80:20 methanol:water solution at − 80 °C to 5 μ l 
of serum sample, followed by vortexing for 10 s, incubation at 4 °C for 10 min, 
and centrifugation at 4 °C and 16,000g for 10 min. To extract metabolites from 
tissue samples, frozen tissue samples were first weighed (~ 20 mg each sample) 
and ground using a Cryomill (Retsch). The resulting powder was then mixed 
with − 20 °C 40:40:20 methanol:acetonitrile:water solution, followed by vortexing 
for 10 s, incubation at 4 °C for 10 min, and centrifugation at 4 °C and 16,000g 
for 10 min. The volume of the extraction solution (in μ l) was 40× the weight 
of tissue (in mg). The supernatant was transferred to LC–MS autosampler vials 
for analysis.
Serum and tissue extracts were analysed using LC–MS. In brief, a quadrupole­ 
orbitrap mass spectrometer (Q Exactive Plus, Thermo Fisher Scientific) operat­
ing in negative ion mode was coupled to hydrophilic interaction chromatography 
via electrospray ionization and used to scan from m/z 73 to 1,000 at 1 Hz and 
140,000 resolution. LC separation was achieved on a XBridge BEH Amide column 
(2.1 mm × 150 mm, 2.5 μ m particle size, 130 Å pore size; Waters) using a gradi­
ent of solvent A (20 mM ammonium acetate + 20mM ammonium hydroxide 
in 95:5 water:acetonitrile, pH 9.45) and solvent B (acetonitrile). Flow rate was 
150 μ l min−1. The gradient was: 0 min, 85% B; 2 min, 85% B; 3 min, 80% B; 5 min, 
80% B; 6 min, 75% B; 7 min, 75% B; 8 min, 70% B; 9 min, 70% B; 10 min, 50% B; 
12 min, 50% B; 13 min, 25% B; 16 min, 25% B; 18 min, 0% B; 23 min, 0% B; 24 min, 
85% B; 30 min, 85% B. Data were analysed using the MAVEN software35. Isotope 
labelling was corrected for natural abundances of 13C, 2H, and 15N. Circulating 
glycerol labelling was determined by first converting serum glycerol to glycerol­ 
3­phosphate using glycerol kinase and then measuring the labelling of glycerol­ 
3­phosphate with LC–MS.
For acetate, circulating metabolite labelling was determined by GC–MS using a 
7890A GC system coupled to a 5975 MSD mass spectrometer (Agilent) after deri­
vatization with 2,3,4,5,6­pentafluorobenzyl bromide as described36. GC separation 
was achieved using an Agilent J&W 122­7033 column (30 m × 0.25 mm × 0.5 μ m). 
The GC temperature program was: 0 min, 35 °C; 6 min, 35 °C; 12 min, 220 °C; 
17 min, 220 °C, followed by returning to 35 °C for the next injection. Other 
GC parameters were: injection volume 1 μ l; He as carrier gas at a flow rate of 
1.2 ml min−1; inlet temperature 250 °C; transfer line temperature 280 °C. Mass 
spectrometry detection was in electron impact ionization mode, with SIM scans 
of m/z 240.3 and 242.3 for unlabelled and 13C2­acetate, respectively.
Free fatty acids in serum samples (thawed on ice) were extracted by adding 200 μ l 
ethyl acetate at room temperature to 10 μ l serum samples, followed by vortexing 
for 10 s, incubation at 4 °C for 10 min, and centrifugation at 16,000g for 10 min. The 
top layer of approximately 190 μ l was transferred to a new glass vial before being 
dried under nitrogen gas flow. The dried extract was dissolved in 100 μ l 1:1 isopopanol: 
methanol before being loaded onto the LC–MS. MS analysis was conducted on an 
Exactive orbitrap mass spectrometer (Thermo Fisher Scientific) scanning at 1 Hz 
and 100,000 resolution operating in negative ion mode. LC separation was on 
reversed­phase ion­pairing chromatography on a Luna C8 column (150 × 2.0 mm, 
3 μ m particle size, 100 Å pore size; Phenomenex) with a gradient of solvent A 
(10 mM tributylamine + 15 mM acetic acid in 97:3 water:methanol, pH 4.5) and 
solvent B (methanol). Flow rate was 250 μ l min−1. The gradient was: 0 min, 80% B; 
10 min, 90% B; 11 min, 99% B; 25 min, 99% B; 26 min, 80% B; 30 min, 80% B.
Data availability. All data are available from the authors upon reasonable request. 
Source Data for Figs 1b–e, 2a–d, 3a–b and 4a–c and Extended Data Figs 2b–d, 
3c, 4a–b, 5a–b, 7a–b, 8a–c and 9a–c are provided with the online version of the 
paper.
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Extended Data Figure 1 | Abundant metabolites in mouse plasma. 
Metabolites (n = 39) with reported concentration greater than 30 μ M in 
mouse plasma. Left bar graph shows those > 100 μ M (n = 17) and right bar 
graph those between 30 μ M and 100 μ M (n = 22). Most of the data are from 
the Mouse Multiple Tissue Metabolome Database (http://mmdb.iab.keio.
ac.jp) (n = 2 mice), except for glucose (n = 6 mice), acetate (n = 3 mice), 
and glycerol (n = 3 mice), whose concentrations were determined in this 
study. The metabolites shown with red bars (n = 30) are those whose 
turnover fluxes have been determined (Table 1). Values are mean ± s.d. 
The concentration cut off of 30 μ M was calculated using equation (1) 
where we used a cardiac output of 0.5 ml g−1 min−1 (see Supplementary 
Note 1 for references) and a turnover flux equating to 10% of glucose Fcirc.
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Extended Data Figure 2 | Determination of turnover flux with  
isotopic tracing. a, Illustration of the mouse infusion experimental  
setup. b, Relative total ion counts (TICs) of serum glucose and lactate  
during 13C­glucose infusion (individual mouse data are shown for three  
mice for each condition). c, Relative TICs of serum glucose and lactate  
during 13C­lactate infusion. d, Glucose (n = 16 for 1× and n = 6 for  
0.5×; P = 0.61) and lactate (n = 18 for 1× and n = 6 for 0.5×; P = 0.50) 
turnover fluxes determined using two different infusion rates 
(mean ± s.d.). P values were determined by a two­tailed unpaired Student’s 
t­test. The 1× infusion rates are listed in Supplementary Table 1.
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Extended Data Figure 3 | Measurement of lactate turnover flux. a, The 
dependence of lactate turnover flux (Fcirc) on the exchanging flux (forward 
(Jf) and reverse (Jr)) between circulating lactate and tissue pyruvate. Rapid 
exchanging flux does not lead to infinitely fast lactate turnover flux. 
Instead, it leads to a lactate turnover flux approaching the net production 
rate of pyruvate (Jg), as illustrated in lower panel. Jt is the pyruvate flux 
going to the TCA cycle. See Supplementary Note 2 for derivation. 
b, Spatial dependence of tracer enrichment. Labelling (L(x)) decreases in 
an exponential manner across a tissue capillary bed (shown schematically 
in the shading of the cylinder representing tissue) with the extent of 
arteriovenous difference in tracer labelling depending on the metabolic 
transformation rate (k) relative to the volumetric blood flow rate (q = Q/V; 
V is tissue volume) as shown in the equation. La and Lv are labelled fraction 
in the artery and the vein, respectively. See Supplementary Note 1. 
c, Lactate labelled fraction in arterial (carotid artery; n = 8 mice, 
mean ± s.d.) and venous (tail vein and vena cava; n = 3 mice, mean ± s.d.) 
serum samples, and in tail snip serum sample (n = 3 mice, mean ± s.d.). 
For comparison of tail snip to vena cava only, samples were collected 
under anaesthesia to allow access to the inferior vena cava. The difference 
in lactate labelling between the carotid artery and tail snip can be used to 
calculate lactate Fcirc using equation (3). With Q = 0.53 ± 0.11 ml min−1 g−1 
and C = 2.5 ± 0.2 mM, together with ≈ .Δ 0 3LLa
, we get lactate Fcirc as  
398 ± 88 nmol min−1 g−1 in the fasted state, which is comparable to the  
value of 374 ± 112 nmol min−1 g−1 obtained with equation (2).  
See Supplementary Note 1 for details.
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Extended Data Figure 4 | Isotopic labelling of tissue TCA intermediates 
reaches steady state after 2.5-h infusion of 13C-glucose. a, Comparison of 
normalized labelling of tissue malate after 2.5 h (n = 5 mice; mean ± s.d.) 
and after 5 h of [U­13C]glucose infusion (n = 3 mice; mean ± s.d.). P values 
were determined by an unpaired Student’s t­test, corrected for multiple 
comparisons using the Holm–Sidak method. Normalized labelling is  
the fraction of 13C atoms in a metabolite divided by the fraction of  
13C atoms in serum glucose. None of the differences are significant 
(P > 0.14 for the brain and liver, and P > 0.98 for other tissues). 
b, Comparison of normalized labelling of tissue succinate after 2.5 h (n = 5 
mice; mean ± s.d.) and after 5 h of [U­13C]glucose infusion (n = 3 mice; 
mean ± s.d.). None of the differences are significant (P > 0.18 for the brain 
and liver, and P > 0.85 for other tissues).
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Extended Data Figure 5 | Isotope labelling of central carbon 
metabolites by 13C-glucose and 13C-lactate. a, Normalized labelling 
by 13C­glucose in fasting mice (n = 3 for pyruvate, 2­oxoglutarate, and 
3­phosphoglycerate, n = 4 for alanine, and n = 5 for all other metabolites; 
mean ± s.d.). b, Normalized labelling by 13C­lactate in fasting mice (n = 3 
for 3­phosphoglycerate and n = 4 for all other metabolites; mean ± s.d.). 
n indicates the number of mice. For the lactate tracer studies, venous 
serum and tissue labelling are normalized to the arterial serum lactate 
labelling. Note that citrate, malate and succinate in tissues turn over 
sufficiently slowly that labelling is robust to the small (< 90 s) delay 
between euthanizing the mouse and tissue harvesting. This delay may, 
however, result in erroneous measurements for tissue lactate, pyruvate 
and glycolytic intermediates. Analyses in the main text are limited to 
the better validated measurements of serum metabolites and tissue TCA 
intermediates. With this caveat in mind, it is nevertheless intriguing that 
lactate labelling varies markedly across tissues. After labelled glucose 
infusion, lactate labelling is highest in the brain, consistent with its use of 
glucose as a major substrate. In the kidneys lactate is strongly labelled after 
glucose infusion, even though TCA intermediates are more labelled after 
lactate infusion. A potential explanation involves tissue heterogeneity; 
for example, the presence both of glycolytic cells that make lactate from 
circulating glucose and of oxidative cells that make TCA intermediates 
from circulating lactate. In other tissues, such as liver, tissue lactate 
labelling is far below circulating lactate and very similar to TCA labelling; 
this may reflect mixing of carbon between lactate and TCA intermediates 
via gluconeogenesis or pyruvate cycling. Another factor diluting tissue 
lactate labelling is that, as blood passes through tissue, owing to the rapid 
exchange between tissue and circulating lactate, the circulating lactate 
loses its labelling, as is evident from the lactate arteriovenous labelling 
difference.
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Extended Data Figure 6 | Concentrations of succinate, malate, and 
citrate in mouse plasma and tissues. Unlike citrate, succinate and 
malate have substantially higher concentrations in tissues than in the 
bloodstream, thus making them a suitable readout for the tissue TCA 
cycle. Data are from the Mouse Multiple Tissue Metabolome Database 
(http://mmdb.iab.keio.ac.jp). Values are mean ± s.d. (n = 2 mice). Note 
that the y­axis is a logarithmic scale.
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Extended Data Figure 7 | Glucose feeds the TCA cycle via circulating 
lactate in anaesthetized mice. a, Turnover fluxes of glucose (n = 4 mice, 
mean ± s.d.) and lactate (n = 3 mice, mean ± s.d.) in anaesthetized mice. 
b, Normalized labelling of serum glucose, lactate, and glutamine in 
anaesthetized mice with 13C­glucose infusion (n = 4 mice; mean ± s.d.) 
and 13C­lactate infusion (n = 3 mice; mean ± s.d.). c, Steady­state whole­
body flux model summarizing glucose and lactate interconversion 
and their feeding to the TCA (see Supplementary Note 4). Values are 
mean ± s.e.m.
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Extended Data Figure 8 | Normalized labelling of serum glutamine, glucose, and lactate, and of tissue TCA intermediates in fed mice. a, 13C­lactate 
infusion (n = 5 mice). b 13C­glutamine infusion (n = 3 mice). c, 13C­glucose infusion (n = 4 mice). Bars are mean ± s.d.
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Extended Data Figure 9 | Scatter plots of normalized labelling of TCA 
intermediates in the three types of tumours by 13C-glucose versus 
that by 13C-lactate. a, KrasLSL-G12D/+Trp53−/− (KP) non­small cell lung 
cancer (n = 3 for 13C­glucose and 13C­lactate infusions, and n = 4 for 
13C­glutamine infusion). b, KrasLSL-G12D/+Stk11−/− (KL) lung cancer  
(n = 3 mice for infusion of each tracer). c, KrasLSL-G12D/+Trp53−/−Ptf1aCRE/+  
(KPf/fC) pancreatic ductal adenocarcinoma (n = 4 for 13C­glucose 
infusion, n = 3 for 13C­lactate and 13C­glutamine infusions). Values are 
mean ± s.d. Data are from Fig. 4a–c. The solid line represents the expected 
labelling by 13C­glucose assuming that glucose feeds the TCA cycle 
solely through circulating lactate. The dashed line indicates the expected 
labelling by 13C­lactate, assuming that lactate feeds the TCA cycle solely 
through circulating glucose.
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Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
6.   Statistical parameters 
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the 
Methods section if additional space is needed). 
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same 
sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more 
complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
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`   Software
Policy information about availability of computer code
7. Software
Describe the software used to analyze the data in this 
study. 
Prism; Matlab (simple scripts)
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made 
available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for 
providing algorithms and software for publication provides further information on this topic.
`   Materials and reagents
Policy information about availability of materials
8.   Materials availability
Indicate whether there are restrictions on availability of 
unique materials or if these materials are only available 
for distribution by a for-profit company.
No unique materials were used.
9.   Antibodies
Describe the antibodies used and how they were validated 
for use in the system under study (i.e. assay and species).
No antibodies were used.
10. Eukaryotic cell lines
a.  State the source of each eukaryotic cell line used. No eukaryotic cell lines were used.
b.  Describe the method of cell line authentication used. No eukaryotic cell lines were used.
c.  Report whether the cell lines were tested for 
mycoplasma contamination.
No eukaryotic cell lines were used.
d.  If any of the cell lines used are listed in the database 
of commonly misidentified cell lines maintained by 
ICLAC, provide a scientific rationale for their use.
No eukaryotic cell lines were used.
`    Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
11. Description of research animals
Provide details on animals and/or animal-derived 
materials used in the study.
12-14 week old C57BL/6 mice of both sexes; 
~12 week old KrasLSL-G12D/+; p53flox/flox (KP) mice of both sexes;  
~12 week old KrasLSL-G12D/+; Lkb1flox/flox (KL) mice of both sexes;  
~10 week old KrasLSL-G12D/+; p53flox/flox; Ptf1aCRE/+ (KPf/fC) mice.
Policy information about studies involving human research participants
12. Description of human research participants
Describe the covariate-relevant population 
characteristics of the human research participants.
This study did not involve human research participants.
